Psychosocial and economic impact of rheumatic diseases on caregivers of Mexican children

Fortuna-Reyna, Brenda de Jesús; Peláez-Ballestas, Ingris; García-Rodríguez, Fernando; Faugier-Fuentes, Enrique; Mendieta-Zerón, Samara; Villarreal-Treviño, Ana Victoria; Rosiles-De la Garza, Sara Georgina; Reyes-Cordero, Greta; Jiménez-Hernández, Sol; Guadarrama-Orozco, Jessica Haydee; de la O-Cavazos, Manuel Enrique; Rubio-Pérez, Nadina

doi:10.1186/s12969-021-00524-2

Pediatric Rheumatology

Table 5 Impact from dimensions of the CAREGIVERS questionnaire and sociodemographic, clinical and healthcare system variables

From: Psychosocial and economic impact of rheumatic diseases on caregivers of Mexican children

		Global	Emotional	Social	Financial	Work	Family	Patient#	Couple°	Spirituality	Networks&
Total n = 200		36 (31–41)	11 (10–13)	6 (4–7)	3 (2–4)	6 (1–7)	8 (7–10)	0 (0–1)	0 (0–1)	1 (0–1)	0 (0–4)
Caregiver’s gender (Male)*		37 (33–40)	11 (10–13)	5 (4–7)	3 (2–4)	7 (6–8)^a	8 (6–9)	0 (0–1)	0 (0–1)	0 (0–1)	0 (0–4)
Patient’s gender (Male)*		37 (33–42)	12 (11–13)^a	6 (4–7)	3 (2–4)	6 (0–7)	9 (7–10)	0 (0–1)	1 (0–1)	1 (0–1)	0 (0–4)
Housewife*		36 (29–40)^c	11 (10–13)	5.5 (4–7)	3 (1–4)	1 (0–6)^b	9 (8–11)^c	0 (0–1)	0 (0–1)	1 (0–1)	0 (0–4)
Paid employment*		36 (32–42)^c	11 (10–13)	6 (4–7)	3 (1–4)	6 (6–7)^b	8 (6–9)^c	0 (0–1)	0 (0–1)	1 (0–1)	0 (0–4)
Partner (No)*		39 (33–44)^b	11 (10–13)	6.5 (5–7)^a	4 (3–5)^a	6 (6–7)	8.5 (6–11)	0 (0–1)	0 (0–0)^a	1 (0–1)	0.5 (0–4)^a
Education ≤9 years*		36 (31–40)	11 (10–13)	6 (4–7)	4 (2–4)^b	6 (0–7)^a	8 (8–10)	0 (0–0)	0 (0–1)	1 (0–1)	0 (0–3)^c
Education > 9 years*		36 (32–42)	11 (10–13)	5 (4–7)	3 (1–4)^b	7 (6–7)^a	8 (6–10)	0 (0–1)	0 (0–1)	1 (0–1)	0 (0–4)^c
JIA**		36 (31–41)	11 (10–13)	5 (4–7)^a	3 (1–4)^a	6 (1–7)	9 (7–10)	0 (0–1)^a	1 (0–1)	1 (0–1)^c	0 (0–4)
JDM**		33.5 (30–39)	11 (9–12)	5.5 (4–6)^a	4 (2–4)^a	6 (0–7)	6 (6–9)	0 (0–1)^a	0 (0–1)	0.5 (0–1)^c	0 (0–1)
JSLE**		36 (33–42)	11 (10–13)	6 (5–8)^a	3 (3–4)^a	6 (1–7)	8 (6–10)	0 (0–0)^a	0 (0–1)	0 (0–1)^c	0 (0–4)
Cutaneous features*		37.5 (32–42)	11 (10–13)	6 (5–7)^a	4 (3–4)^a	6 (0–7)	8.5 (7–10)	0 (0–0)^c	0 (0–1)	0.5 (0–1)	0 (0–4)
Musculoskeletal features*^d		36 (31–41)	11 (10–13)	5 (4–7)	3 (2–4)	6 (0–7)	9 (7–10)	0 (0–1)^a	0 (0–1)	1 (0–1)	0 (0–4)
Systemic features*^e		37 (32–42)	11.5 (10–13)	6 (5–7)^a	4 (2–4)^a	6 (1–7)	8.5 (7–11)	0 (0–0)^a	0 (0–1)	1 (0–1)	0 (0–4)
Hospitalization (Yes)*		36 (31–40)	11 (10–13)	6 (4–7)^c	3.5 (2–4)^a	6 (0–7)	8 (6–10)	0 (0–0)^a	0 (0–1)	1 (0–1)	0 (0–4)
Disability (Yes)*		36 (31–40)	11 (10–13)	6 (5–8)^a	4 (3–5)^a	6 (0–6)^a	9 (8–10)	0 (0–1)	0 (0–1)	0 (0–1)	0 (0–4)
Active Disease (Yes)*		36 (32–41)	11 (10–13)	6 (5–7)^a	4 (3–4)^a	6 (0–6)^a	9 (7–10)	0 (0–1)	0 (0–1)	1 (0–1)	0 (0–4)
Treatment (Yes)*	NSAID	37 (31–42)^c	11 (10–13)^c	6 (4–7)	3 (2–4)^a	6 (0–7)^a	9 (8–10)^c	0 (0–1)	1 (0–1)^a	1 (0–1)	0 (0–4)
	DMARD	36 (32–40)	11 (10–13)	5 (4–7)	3 (1–4)^c	6 (1–7)	8 (7–10)	0 (0–1)	0 (0–1)	1 (0–1)	0 (0–4)
	GC	36.5 (32–41)	11 (10–13)	6 (5–7)^a	4 (3–4)^b	6 (0–7)	8 (7–10)	0 (0–0)^a	0 (0–1)	0.5 (0–1)	0 (0–4)
	bDMARD (No)	36 (32–41)^a	11 (10–13)	6 (4–7)^a	3 (2–4)^a	6 (0–7)	9 (7–11)^c	0 (0–1)	0 (0–1)	1 (0–1)	0 (0–4)
PartC**		37 (32–41)^a	11 (10–13)	6 (5–7)^b	4 (3–4)^b	6 (0–6)^b	9 (8–10)^a	0 (0–1)^a	0 (0–1)	1 (0–1)	0 (0–4)
FullC**		33 (31–36)^a	11 (10–12)	4 (3–6)^b	1 (1–2)^b	7 (6–7)^b	8 (6–9)^a	0 (0–1)^a	0 (0–1)	1 (0–1)	0 (0–2)
PRI**		34.5 (28–45)^a	12.5 (9–13)	4.5 (3–6)^b	1.5 (1–3)^b	7 (1–8)b	7.5 (6–10)^a	1 (0–1)a	0.5 (0–1)	1 (0–1)	2 (0–4)
More than one hour to the center *		36 (32–40)	11 (10–13)	6 (4–7)^a	3.5 (2–4)^a	6 (0–7)^c	9 (8–10)^a	0 (0–1)	0 (0–1)	1 (0–1)	0 (0–2)^a

Note: All values are expressed as median (IQR). IQR Interquartile range, JIA Juvenile Idiopathic Arthritis, JSLE Juvenile Systemic Lupus Erythematosus, JDM Juvenile Dermatomyositis, NSAID Nonsteroidal anti-inflammatory drugs, DMARD Disease-modifying antirheumatic drugs, GC Systemic Glucocorticoids, bDMARD Biological therapy
PartC Partial Coverage Healthcare system, FullC Total Coverage Healthcare system, PRI Private Healthcare System
^a p < 0.05
^b p < 0.001
^c Tendency
^d Includes arthritis and myositis
^e Includes neurological, hematological, pulmonary, gastrointestinal, cardiovascular, nephritis, serositis, adenomegaly, hepatomegaly, hepatitis, thyroiditis and uveitis manifestations
* Analyzed with Chi square test
** Analyzed with Kruskal-Wallis test
# Relationship of the caregiver with the patient
° Relationship of the caregiver with partner
& Social Network

Back to article page

ISSN: 1546-0096

Contact us

Submission enquiries: Access here and click Contact Us
General enquiries: info@biomedcentral.com